GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta-analysis of Treatment Effects from 37 Randomized Trials

American Journal of Kidney Diseases

Volumn 64, Issue 6, 2014, Pages 848-859

  Inker, Lesley A ^a   Lambers Heerspink, Hiddo J ^b   Mondal, Hasi ^c   Schmid, Christopher H ^d   Tighiouart, Hocine ^c   Noubary, Farzad ^c   Coresh, Josef ^e   Greene, Tom ^f   Levey, Andrew S ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c TUFTS UNIVERSITY   (United States)

^d BROWN UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

chronic kidney disease (CKD); eGFR trajectory; end stage renal disease (ESRD); estimated glomerular filtration rate (eGFR) decline; kidney disease outcome; kidney disease progression; Kidney end point; renal end point; renal function; surrogate end point; treatment effect

Indexed keywords

CREATININE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; CREATININE BLOOD LEVEL; END STAGE RENAL DISEASE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; META ANALYSIS; PROTEIN RESTRICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMATIC REVIEW; BIOASSAY; KIDNEY FAILURE, CHRONIC; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; STANDARDS; TREATMENT OUTCOME;

ENDPOINT DETERMINATION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84911421306     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.08.017     Document Type: Article

References (62)

1. J. Coresh, T.C. Turin, and K. Matsushita Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality JAMA 311 24 2014 2518 2531
2. A.S. Levey, L.A. Inker, and K. Matsushita GFR Decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration Am J Kidney Dis 64 6 2014 821 835
3. H.J. Lambers Heerspink, H. Tighiouart, and Y. Sang GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials Am J Kidney Dis 64 6 2014 860 866
4. T. Greene, C.-C. Teng, and L.A. Inker Utility and validity of estimated GFR-based surrogate time-to-eventend points in CKD: a simulation study Am J Kidney Dis 64 6 2014 867 879
5. N. Stoycheff, K. Pandya, and A. Okparavero Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset Nephrol Dial Transplant 26 3 2011 848 857
6. L.A. Inker, A.S. Levey, K. Pandya, N. Stoycheff, A. Okparavero, and T. Greene Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis Am J Kidney Dis 64 1 2014 74 85
7. A.L. Kamper, S. Strandgaard, and P.P. Leyssac Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial Am J Hypertens 5 7 1992 423 430
8. B.U. Ihle, J.A. Whitworth, S. Shahinfar, A. Cnaan, P.S. Kincaid-Smith, and G.J. Becker Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial Am J Kidney Dis 27 4 1996 489 495
9. F.F. Hou, X. Zhang, and G.H. Zhang Efficacy and safety of benazepril for advanced chronic renal insufficiency N Engl J Med 354 2 2006 131 140
10. T. Hannedouche, P. Landais, and B. Goldfarb Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure BMJ 309 6958 1994 833 837
11. T.H. Jafar, P.C. Stark, and C.H. Schmid Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis Ann Intern Med 139 4 2003 244 252
12. G. Maschio, D. Alberti, and G. Janin Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group N Engl J Med 334 15 1996 939 945
13. B.M. Brenner, M.E. Cooper, and D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 12 2001 861 869
14. P. Ruggenenti, A. Perna, and G. Gherardi Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria Lancet 354 9176 1999 359 364
15. G.G. van Essen, A.J. Apperloo, and P.L. Rensma Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int Suppl 63 1997 S58 S62
16. J.T. Wright Jr., G. Bakris, and T. Greene Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial JAMA 288 19 2002 2421 2431
17. E.J. Lewis, L.G. Hunsicker, and W.R. Clarke Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 12 2001 851 860
18. E.J. Lewis, L.G. Hunsicker, R.P. Bain, and R.D. Rohde The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group N Engl J Med 329 20 1993 1456 1462
19. P.K. Li, C.B. Leung, and K.M. Chow Hong Kong Study Using Valsartan in IgA Nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study Am J Kidney Dis 47 5 2006 751 760
20. M. Praga, E. Gutierrez, E. Gonzalez, E. Morales, and E. Hernandez Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial J Am Soc Nephrol 14 6 2003 1578 1583
21. P. Zucchelli, A. Zuccala, and M. Borghi Long-term comparison between captopril and nifedipine in the progression of renal insufficiency Kidney Int 42 2 1992 452 458
22. R.O. Estacio, B.W. Jeffers, N. Gifford, and R.W. Schrier Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes Diabetes Care 23 suppl 2 2000 B54 B64
23. S. Klahr, A.S. Levey, and G.J. Beck The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group N Engl J Med 330 13 1994 877 884
24. P. Ruggenenti, A. Perna, and G. Loriga Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial Lancet 365 9463 2005 939 946
25. J.V. Donadio Jr., T.S. Larson, E.J. Bergstralh, and J.P. Grande A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy J Am Soc Nephrol 12 4 2001 791 799
26. G. Frisch, J. Lin, and J. Rosenstock Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial Nephrol Dial Transplant 20 10 2005 2139 2145
27. E.J. Lewis, L.G. Hunsicker, S.P. Lan, R.D. Rohde, and J.M. Lachin A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group N Engl J Med 326 21 1992 1373 1379
28. B.D. Maes, R. Oyen, and K. Claes Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study Kidney Int 65 5 2004 1842 1849
29. J.V. Donadio Jr., J.P. Grande, E.J. Bergstralh, R.A. Dart, T.S. Larson, and D.C. Spencer The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group J Am Soc Nephrol 10 8 1999 1772 1777
30. T.M. Chan, K.C. Tse, C.S. Tang, M.Y. Mok, and F.K. Li Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis J Am Soc Nephrol 16 4 2005 1076 1084
31. F.A. Houssiau, C. Vasconcelos, and D. D'Cruz Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide Arthritis Rheum 46 8 2002 2121 2131
32. C. Ponticelli, P. Altieri, and F. Scolari A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy J Am Soc Nephrol 9 3 1998 444 450
33. C. Ponticelli, P. Zucchelli, and P. Passerini A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy N Engl J Med 320 1 1989 8 13
34. C. Ponticelli, P. Zucchelli, P. Passerini, and B. Cesana Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group N Engl J Med 327 9 1992 599 603
35. M. Praga, V. Barrio, G.F. Juarez, and J. Luno Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial Kidney Int 71 9 2007 924 930
36. C. Ponticelli, P. Passerini, and M. Salvadori A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy Am J Kidney Dis 47 2 2006 233 240
37. C. Manno, D.D. Torres, M. Rossini, F. Pesce, and F.P. Schena Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy Nephrol Dial Transplant 24 12 2009 3694 3701
38. C. Pozzi, S. Andrulli, and L. Del Vecchio Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial J Am Soc Nephrol 15 1 2004 157 163
39. R. Katafuchi, K. Ikeda, and T. Mizumasa Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy Am J Kidney Dis 41 5 2003 972 983
40. C. Pozzi, S. Andrulli, and A. Pani IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine J Nephrol 26 1 2013 86 93
41. C. Pozzi, S. Andrulli, and A. Pani Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy J Am Soc Nephrol 21 10 2010 1783 1790
42. A.S. Levey, L.A. Stevens, and C.H. Schmid A new equation to estimate glomerular filtration rate Ann Intern Med 150 9 2009 604 612
43. H. Skali, H. Uno, A.S. Levey, L.A. Inker, M.A. Pfeffer, and S.D. Solomon Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation Am Heart J 162 3 2011 548 554
44. W. Viechtbauer Conducting meta-analyses in R with the metafor package J Stat Softw 36 3 2010 1 48
45. J.P. Higgins, S.G. Thompson, and D.J. Spiegelhalter A re-evaluation of random-effects meta-analysis J R Stat Soc Ser A Stat Soc 172 1 2009 137 159
46. P.D.G. Steel, and J. Kammeyer-Mueller Bayesian variance estimation for meta-analysis: quantifying our uncertainty Organizational Res Methods 11 2008 54 78
47. M. Buyse, and G. Molenberghs Criteria for the validation of surrogate endpoints in randomized experiments Biometrics 54 1998 1014 1029
48. Plummer M. JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling. Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003); March 20-22, 2003; Vienna, Austria.
49. D. Echt, R. Liebson, and N. Mitchell Mortality and morbidity in patient receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial N Engl J Med 324 1991 781 788
50. T.R. Fleming, and D.L. DeMets Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125 7 1996 605 613
51. S.G. Baker, and B.S. Kramer A perfect correlate does not a surrogate make BMC Med Res Methodol 3 2003 16
52. R. Katz Biomarkers and surrogate markers: an FDA perspective NeuroRx 1 2 2004 189 195
53. A.J. Apperloo, D. de Zeeuw, and P.E. de Jong Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease Kidney Int Suppl 45 1994 S174 S178
54. F.A. Holtkamp, D. de Zeeuw, and M.C. Thomas An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function Kidney Int 80 3 2011 282 287
55. D.M. Kent, and R.A. Hayward Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification JAMA 298 10 2007 1209 1212
56. C.H. Schmid, J. Lau, M.W. McIntosh, and J.C. Cappelleri An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials Stat Med 17 17 1998 1923 1942
57. Modification of Diet in Renal Disease Study Group; Levey AS, Bosch JP, Coggins CH, et al. Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1996;7:556-565.
58. L.A. Stevens, J. Coresh, T. Greene, and A.S. Levey Assessing kidney function - measured and estimated glomerular filtration rate N Engl J Med 354 23 2006 2473 2483
59. H.J. Lambers Heerspink, M. Weldegiorgis, and L.A. Inker Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT) Am J Kidney Dis 63 2 2014 244 250
60. S. Czernichow, A. Zanchetti, and F. Turnbull The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials J Hypertens 29 1 2011 4 16
61. F. Turnbull, B. Neal, and M. Pfeffer Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system J Hypertens 25 5 2007 951 958
62. C. Baigent, A. Keech, and P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 9493 2005 1267 1278